Filing Flows › Core Laboratories (CLB) › Q3 2026 › vs Q2 2026
Core Laboratories (CLB) Q3 2026 vs Q2 2026 (quarter over quarter)
Core Laboratories's revenue rose $7.5M (+6%) from $125M in Q2 2026 to $132M in Q3 2026. The biggest changes: Product +$5.7M (+19%); Service +$1.7M (+2%). Operating margin 9.1% against 7.3% (+1.8 pts).
Core Laboratories, Q3 2026: revenue $132M (-2% year over year), operating margin 9.1%, net earnings $5.4M, operating cash flow $5.0M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 9.1% | 7.3% | +1.8 pts |
| Net margin | 4.1% | 4.8% | -0.7 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Service | $96.0M | $94.3M | $1.7M | +2% |
| Product | $36.1M | $30.3M | $5.7M | +19% |
| Revenue | $132M | $125M | $7.5M | +6% |
| Operating profit | $12.1M | $9.2M | $2.9M | +32% |
| Costs & expenses | $120M | $115M | $4.6M | +4% |
| Pre-tax earnings | $9.3M | $6.3M | $3.0M | +47% |
| Other expense, net | $2.8M | $2.8M | −$60K | -2% |
| Cost of revenue | $105M | $101M | $3.7M | +4% |
| General & admin | $11.3M | $11.0M | $315K | +3% |
| Other operating costs | $3.7M | $3.1M | $518K | +17% |
| Net earnings | $5.4M | $6.0M | −$512K | -9% |
| Minority interests | $19K | −$158K | $177K | — |
| Income tax | $3.8M | $507K | $3.3M | +653% |
| Operating cash sources | $10.5M | $10.7M | −$231K | -2% |
| Depreciation & amortization | $3.7M | $3.8M | −$101K | -3% |
| Share-based compensation | $1.3M | $902K | $382K | +42% |
| Working capital & other | $5.5M | $2.9M | $2.6M | +91% |
| Operating cash flow | $5.0M | $7.8M | −$2.8M | -36% |
Questions
How much did Core Laboratories's revenue grow quarter over quarter in Q3 2026?
Core Laboratories's revenue rose $7.5M (+6%) from $125M in Q2 2026 to $132M in Q3 2026.
What drove Core Laboratories's revenue change in Q3 2026?
Product +$5.7M (+19%); Service +$1.7M (+2%).